The researchers said: "Our findings highlight the potential for GLP-1 medications to significantly reshape consumer food demand, a trend with increasingly important implications for the food industry as adoption continues to grow." The study highlights that users show the "largest" spending reductions in "ultra-processed categories." The spending on products such as chips, baked goods, sides and cookies fell on average between 6.7% and 11.1%
Inside the cell: molecular stress response pathways in diabetes pathogenesis
More recently, the semaglutide STEP 3 study, which compared 2.4mg of once weekly semaglutide to placebo and included intensive behavioral therapy in both groups (hypocaloric diet plus exercise), reported 5% weight loss in 87% of those treated with semaglutide and 48% of those treated with placebo lost 5% body weight, and 10% weight loss in 75.3% treated with semaglutide and 27% treated with placebo (14)
In the trial, researchers randomly assigned 3,533 adults with type 2 diabetes who were prescribed a stable dose of renin-angiotensin system inhibitors, 1:1, to weekly 1 mg semaglutide injection or placebo
/product/99/7475523/2.jpg?7369)
